Detalhe da pesquisa
1.
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Nat Commun;
15(1): 2805, 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555285
2.
Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
Cancer Gene Ther;
31(5): 721-735, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38424218
3.
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
Oncologist;
28(10): 919-e972, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279797
4.
Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047.
Cancer Discov;
13(5): 1084-1099, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37067240
5.
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.
Front Pharmacol;
14: 1136317, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37063293
6.
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
J Exp Clin Cancer Res;
42(1): 102, 2023 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37101182
7.
Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer.
Cancers (Basel);
15(7)2023 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37046596
8.
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
J Exp Clin Cancer Res;
42(1): 76, 2023 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36991390
9.
Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Clin Cancer Res;
29(2): 501, 2023 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36647676
10.
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Clin Cancer Res;
29(8): 1450-1459, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36705597
11.
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.
Med;
4(1): 15-30.e8, 2023 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36513065
12.
Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth.
J Biol Chem;
299(1): 102766, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36470425
13.
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Clin Cancer Res;
29(2): 349-363, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099324
14.
NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER- Breast Cancer.
bioRxiv;
2023 Dec 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38187532
15.
Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients.
bioRxiv;
2023 Dec 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38187660
16.
Photochemical Dimerization of Plakinidine B Leads to Potent Inhibition of the E3 Ubiquitin-Protein Ligase CBL-B.
Org Lett;
24(51): 9468-9472, 2022 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36516994
17.
Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy.
Cells;
11(23)2022 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36496977
18.
Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density.
Redox Biol;
58: 102529, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375380
19.
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis.
Cancer Res Commun;
2(10): 1144-1161, 2022 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36388465
20.
Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP.
Pharmacol Res Perspect;
10(4): e00993, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35929764